Dr Koehi Shitara speaks to ecancer about the expanded efficacy, safety, and subgroup analyses from CheckMate 649. This study investigated nivolumab plus chemotherapy versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophagal adenocarcinoma. He initially talks about the background of this study. Dr Shitara lists the results from the primary analysis and then discusses the results of the expanded analysis. He enlists the methodology of the study and explains the key results. He says that the addition of NIVO to chemo demonstrated improved OS and PFS benefit in all randomised patients, along with an acceptable safety profile and maintained tolerability as well as QoL, providing further support for NIVO + chemo as a standard 1L treatment for advanced GC/GEJC/EAC.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
